Report period | 2018 | 2019 | 2020 | 2021 | 2022 | Q3 23 |
---|---|---|---|---|---|---|
End date of the reporting period | ||||||
Capitalization, $ | ||||||
Capitalization, $ | ||||||
Enterprise Value | ||||||
Book Value | ||||||
Shareholders Book Value | ||||||
Current liabilities | ||||||
Noncurrent liabilities | ||||||
Total liabilities | ||||||
Debt | ||||||
Cash and cash equivalents | ||||||
Net debt | ||||||
Assets | ||||||
Total ordinary shares | ||||||
Ordinary share price |
Ticker | Name | Type | Nominal value | ISIN | Price |
---|---|---|---|---|---|
SGHT:US | Sight Sciences | Common share | - | US82657M1053 | $5.13 |
Company name | Sight Sciences |
---|---|
Tags | #ophthalmology, #medical equipment |
Sector | Health Care / Health Care Equipment & Services / Health Care Equipment & Supplies / Health Care Equipment |
Business address | 4040 Campbell Avenue Suite 100 Menlo Park, CA 94025 United States |
Mailing address | 4040 Campbell Avenue Suite 100 Menlo Park, CA 94025 United States |
Website | investors.sightsciences.com |